262 related articles for article (PubMed ID: 19122005)
1. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
2. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
3. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
4. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
5. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
6. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
[TBL] [Abstract][Full Text] [Related]
7. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
[TBL] [Abstract][Full Text] [Related]
8. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
9. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
10. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
[TBL] [Abstract][Full Text] [Related]
11. A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3.
Pennington MW; Harunur Rashid M; Tajhya RB; Beeton C; Kuyucak S; Norton RS
FEBS Lett; 2012 Nov; 586(22):3996-4001. PubMed ID: 23063513
[TBL] [Abstract][Full Text] [Related]
12. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
Kalman K; Pennington MW; Lanigan MD; Nguyen A; Rauer H; Mahnir V; Paschetto K; Kem WR; Grissmer S; Gutman GA; Christian EP; Cahalan MD; Norton RS; Chandy KG
J Biol Chem; 1998 Dec; 273(49):32697-707. PubMed ID: 9830012
[TBL] [Abstract][Full Text] [Related]
13. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.
Varga Z; Gurrola-Briones G; Papp F; Rodríguez de la Vega RC; Pedraza-Alva G; Tajhya RB; Gaspar R; Cardenas L; Rosenstein Y; Beeton C; Possani LD; Panyi G
Mol Pharmacol; 2012 Sep; 82(3):372-82. PubMed ID: 22622363
[TBL] [Abstract][Full Text] [Related]
14. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
15. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
16. Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria.
Chang SC; Galea CA; Leung EW; Tajhya RB; Beeton C; Pennington MW; Norton RS
Toxicon; 2012 Oct; 60(5):840-50. PubMed ID: 22659540
[TBL] [Abstract][Full Text] [Related]
17. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
18. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin.
Pennington MW; Lanigan MD; Kalman K; Mahnir VM; Rauer H; McVaugh CT; Behm D; Donaldson D; Chandy KG; Kem WR; Norton RS
Biochemistry; 1999 Nov; 38(44):14549-58. PubMed ID: 10545177
[TBL] [Abstract][Full Text] [Related]
19. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
20. A potent and selective peptide blocker of the Kv1.3 channel: prediction from free-energy simulations and experimental confirmation.
Rashid MH; Heinzelmann G; Huq R; Tajhya RB; Chang SC; Chhabra S; Pennington MW; Beeton C; Norton RS; Kuyucak S
PLoS One; 2013; 8(11):e78712. PubMed ID: 24244345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
